IDE-ALERTS Continued Access Study (ALERTS-CAS)
ALERTS Continued Access Study- IDE G060259 Supplement
Sponsor: Angel Medical Systems
Terminated
FDA Approval was received for the Model AMSG3-E IMD and therefore commercial implants could be started. There was no longer any need to implant under the CAS. CAS patients were transitioned to commercial patients.
This NA trial investigates Acute Coronary Syndrome and is currently terminated or withdrawn. Angel Medical Systems leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jul 2022 — Jul 2024 [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Oct 2021 — Jul 2022 [monthly]
Active Not Recruiting NA
Status: Enrolling By Invitation → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Enrolling By Invitation NA
▶ Show 4 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Enrolling By Invitation NA
Status: Withheld → Enrolling By Invitation · Phase: None → NA
-
Aug 2020 — Oct 2020 [monthly]
Withheld
-
May 2020 — Aug 2020 [monthly]
Withheld
-
Apr 2020 — May 2020 [monthly]
Withheld
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Angel Medical Systems
For direct contact, visit the study record on ClinicalTrials.gov .